NEW YORK, Feb. 5, 2018 /PRNewswire/ — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ACAD, AKAO, ACHN, and ACOR which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Biotechnology space, which includes companies that are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. Under assessment this morning are: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR). All you have to do is sign up today for this free limited time offer by clicking the link below.
San Diego, California headquartered ACADIA Pharmaceuticals Inc.’s stock finished last Friday’s session 4.30% lower at $28.96. A total volume of 1.06 million shares was traded. The Company’s shares are trading below their 50-day moving average by 0.98%. Additionally, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 46.90. Get the full research report on ACAD for free by clicking below at: www.wallstequities.com/registration/?symbol=ACAD
On Friday, shares in South San Francisco, California-based Achaogen Inc. ended the session 3.63% lower at $10.74. The stock recorded a trading volume of 1.15 million shares, which was higher than its three months average volume of 1.13 million shares. The Company’s shares have gained 1.32% in the last month. The stock is trading 5.13% below its 50-day moving average. Moreover, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 44.82.
On January 25th, 2018, Achaogen announced that on January 19th, 2018, the compensation committee of its Board of Directors granted six new employees the option to purchase an aggregate of 30,000 shares of the Company’s common stock and 15,001 restricted stock units. Each stock option has an exercise price per share equal to $11.54, which was the closing trading price on January 19th, 2018. Access the free research report on AKAO now by signing up at: www.wallstequities.com/registration/?symbol=AKAO
New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.’s shares declined 1.47%, closing the session at $2.68 with a total trading volume of 1.33 million shares. The stock is trading 10.21%